Occam Places Brian Piekos as CFO of Elicio Therapeutics
Elicio Therapeutics (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, using its proprietary lymph node-targeting Amphiphile technology. Occam placed Brian Piekos as the company's Chief Financial Officer, in parallel with the closing of Elicio's previously announced merger with Angion Biomedica Corp.
Brian brings well-honed operational discipline and capital markets wisdom to the party. Most recently, Brian served as CFO of Gemini Therapeutics. Prior to joining Gemini, Brian was CFO at AMAG Pharmaceuticals upon the company’s sale in November 2021. Before that, Brian held leadership roles in Corporate Finance, Tax and Treasury at Cubist Pharmaceuticals. He began his career as a healthcare investment banker at Needham & Company and Leerink Partners.
Elicio is a longstanding client of Occam's. Previous placements include Head of R&D and Chief Medical Officer Chris Haqq, Chief Business Officer Annette Matthies, and Board Director Daphne Karydas.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.